[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-neoplastic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-neoplastic-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,65,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100587404","navigation-interventions-to-improve-cascade-genetic-testing-among-relatives-of-patients-with-hereditary-cancer-syndromes-100587404",false,"NCT06927947","Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes","Testing Effectiveness of Navigation Interventions to Increase Uptake of Cascade Genetic Testing Among Relatives of Individuals Diagnosed With Hereditary Cancer Syndromes","Inclusion Criteria:\n\n* PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome\n* PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic\n* PROBANDS: ≥ 18 years old\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* RELATIVES: Biological relative of proband\n* RELATIVES: ≥ 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n* RELATIVES: Have not completed germline genetic testing, per self-report at baseline\n\nExclusion Criteria:\n\n* RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline",true,"ALL","18 Years",{"count":20,"type":21},625,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.",[27,28],"Hereditary Malignant Neoplasm","Hereditary Neoplastic Syndrome","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2025-09-23",{"date":37,"type":21},"2026-09-30",{"name":39,"class":40},"University of Michigan Rogel Cancer Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100634647","a-web-based-program-kindred-to-improve-the-understanding-of-genetic-cancer-risk-and-cancer-genetic-testing-in-african-american-families-100634647","NCT07542405","A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families","Kindred: Family Centered Approaches to Promoting Cascade Screening for Hereditary Cancer Syndromes Among African Americans","Inclusion Criteria:\n\n* PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing\n* PROBANDS: \\>= 18-years-old\n* PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities)\n* RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing\n* RELATIVES: \\>= 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n\nExclusion Criteria:\n\n* PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative\n* PROBANDS: Under 18-years-old\n* PROBANDS: Did not receive cancer genetic testing\n* PROBANDS: Does not speak or read English\n* PROBANDS: Does not have internet access\n* PROBANDS: Does not identify as African American or Black\n* RELATIVES: Not a biological relative of proband\n* RELATIVES: Under 18-years-old\n* RELATIVES: Does not speak or read English\n* RELATIVES: Does not have internet access",{"count":50,"type":21},150,[24],"This clinical trial studies whether a web-based program, Kindred, works to improve the understanding of genetic cancer risk and cancer genetic testing in African American families. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or a family history of cancer means individuals are more likely to have a genetic change. If a genetic change is identified in a family, other relatives can choose to undergo hereditary cancer genetic testing to better understand their cancer risk. In families where a genetic change is not identified, or results are uncertain, relatives may also benefit from discussing their cancer risk with providers and, in some cases, getting hereditary cancer genetic testing themselves. Research has shown that African Americans are less likely than other racial groups to engage in cancer genetic testing. Kindred is an online tool that provides information so individuals can learn about their cancer genetic test results, how cancer genetic testing can help individuals and families understand their overall cancer risk (and strategies for reducing risk), and ways to talk with each other about cancer risk and health. This may be an effective way to improve the understanding of genetic cancer risk and cancer genetic testing in African American families.",[54,55,28,56],"BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome","BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome","Lynch Syndrome","NOT_YET_RECRUITING","2026-05-18",{"date":60,"type":33},"2026-05-19",{"date":32,"type":21},{"date":63,"type":21},"2028-06",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100282586","pre-myeloid-cancer-and-bone-marrow-failure-clinic-study-100282586","NCT02958462","Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","Inclusion Criteria:\n\n* Patients with idiopathic cytopenias of unclear significance (ICUS)\n* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \\[CHIP\\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)\n* Patients with clonal cytopenias of undetermined significance (CCUS)\n* Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders\n* Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.\n* Low risk MDS (idiopathic dysplasia of unclear significance)\n* Family member of a patient with one of the above conditions\n* Patient at high risk or suspected of developing one of the above conditions\n\nExclusion Criteria:\n\n* Patients under 18 years of age",{"count":72,"type":21},2000,[24],"This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.",[76,77,78,79,80,81,82,83,84,28,85,86,87],"Myeloid Malignancy","Inherited Bone Marrow Failure Syndrome","Clonal Expansion","Cytopenia","Bone Marrow Failure Syndrome","Clonal Cytopenia of Undetermined Significance","Clonal Hematopoiesis of Indeterminate Potential","Hematologic Neoplasms","Hematopoietic and Lymphatic System Neoplasm","Idiopathic Cytopenia of Undetermined Significance","Idiopathic Dysplasia of Uncertain Significance","Low Risk Myelodysplastic Syndrome","2026-02-20",{"date":90,"type":33},"2026-02-23",{"date":92,"type":33},"2017-01-16",{"date":94,"type":21},"2035-09-15",{"name":96,"class":40},"Mayo Clinic",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100400493","identifying-and-caring-for-individuals-with-inherited-cancer-syndrome-100400493","NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome","Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes","Inclusion Criteria:\n\n* ALL COHORTS: 18 years of age or older\n* Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent\n* Retrospective COHORT A: Patients may or may not be diagnosed with cancer\n* Retrospective COHORT A: Patients have received genetic counseling in the past 5 years\n* Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent\n* COHORT A: Patients may or may not be diagnosed with cancer\n* COHORT A: Patients have received genetic counseling in the past 1 - 2 years\n* COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: INCLUSIVE of no contact list to exclude from Cohort B\n* COHORT B: Creation of secure Healthy Oregon Project (HOP) app account\n* COHORT B: Consent to this project, either hard or electronic signature\n* COHORT B: Consent to the HOP repository, either hard or electronic signature\n* COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample\n* COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and\u002For in situ breast cancer\n* COHORT B: Must have had an encounter within past twelve months\n* COHORT B: Exclude Cohort A\n* COHORT C: Creation of secure Hop app account\n* COHORT C: Consent to this project, either hard or electronic signature\n* COHORT C: Consent to the HOP repository, either hard or electronic signature\n* COHORT C: Choosing to submit a DNA sample",{"count":106,"type":21},27500,[24],"This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.",[110,111,112,28,56,113],"BRCA1\u002F2-Associated Hereditary Breast and Ovarian Cancer Syndrome","Breast Ductal Carcinoma In Situ","Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","2026-01-21",{"date":116,"type":33},"2026-01-23",{"date":118,"type":33},"2020-03-09",{"date":120,"type":21},"2026-03-31",{"name":122,"class":40},"OHSU Knight Cancer Institute",2]